Diagnosis and Treatment of Generalized Anxiety Disorder in Japan: Psychiatric Specialist Survey
DOI: https://doi.org/10.2147/ndt.s456276
IF: 2.989
2024-05-15
Neuropsychiatric Disease and Treatment
Abstract:Keisuke Nomoto, 1 Osamu Takashio, 2 Satoshi Matsuyama, 1 Shingo Higa, 1 Tempei Otsubo 3 1 Medical Affairs, Viatris Pharmaceuticals Japan Inc., Tokyo, Japan; 2 Department of Neuropsychiatry, Showa University East Hospital, Tokyo, Japan; 3 Department of Psychosomatic and Psychiatric Medicine, Tokyo Women's Medical University Adachi Medical Center, Tokyo, Japan Correspondence: Keisuke Nomoto, Medical Affairs, Viatris Pharmaceuticals Japan Inc., Holland Hills Mori Tower, 5-11-2 Toranomon, Minato-ku, Tokyo, 105-0001, Japan, Tel +81-3-5656-0400, Fax +81-3-5656-0603, Email Purpose: Generalized anxiety disorder (GAD) is a suboptimally managed chronic recurring psychiatric condition with a lifetime prevalence of 2.6% in Japan. We assessed the current status of GAD management in Japan. Patients and Methods: This was an observational, cross-sectional study conducted through an anonymous web-based survey in Japan from December 12– 16, 2022. Psychiatrists and psychosomatic medicine physicians who agreed to participate and saw ≥ 10 outpatients in the previous month were eligible. Survey questionnaire comprised 37 single/multiple choice, numerical entry, or open-ended questions in Japanese. Results: Among 509 participants (493 psychiatrists and 16 psychosomatic medicine physicians), 96.9% were aware of GAD. On average, 12.4 outpatients and 1.0 inpatient were diagnosed with GAD per physician per month. Of 433 physicians having patients diagnosed with GAD, 46.9% used operational diagnostic tools; among these, DSM-5 diagnostic criteria were used by 81.5% physicians. The majority (54.7%) of participants did not use a self-administered rating scale; depression scales were used more than anxiety scales. Among these 433 physicians, 96.8% used selective serotonin reuptake inhibitors for GAD management, and 79.2% used it as the first choice; of 431 physicians who prescribed drug therapy, 54.3% gave antidepressant monotherapy as first choice. The most frequent symptom in patients diagnosed with GAD was excessive anxiety/worry (96.5%); depression was the most commonly reported comorbidity (84.3%) as per physicians aware of GAD (N=508). Conclusion: This study illustrates that although GAD awareness is high among Japanese psychiatric specialists, GAD is not frequently diagnosed using operational diagnostic approaches. Due to a lack of Japanese guidelines for GAD diagnosis and treatment, diverse international guidelines are followed, with similar treatment paradigms as that of depression. This may not be an optimal approach given cultural/geographical differences. These findings highlight the need for uniform diagnosis and treatment recommendations for GAD management in Japan. Clinical Trial Registration: UMIN-CTR: UMIN000049572. Keywords: anxiety, GAD, psychiatrist, psychosomatic medicine physician, survey Generalized anxiety disorder (GAD) is a chronic and recurring psychiatric condition characterized by at least 6 months of persistent and excessive uncontrollable anxiety and worry about multiple events, on more days than days without such anxiety or worry. Key symptoms of GAD include restlessness, irritability, difficulty concentrating, muscle tension, sleep disturbances, and fatigue combined with significant distress or impairment in social, occupational, or other areas of function. 1 Globally, the lifetime prevalence of GAD, evaluated based on the DSM-5 and using data from the World Health Organization World Mental Health Survey Initiative, was 3.7% for the period between 2001 and 2012. 2 Based on the World Mental Health Survey data from 2002–2006, the lifetime and 12-month prevalence of GAD per DSM-5 in Japan were 2.6% and 1.2%, respectively, which are marginally lower than that reported in other developed countries. 2 Despite a substantial prevalence, GAD remains insufficiently managed in Japan. Approximately 70% of all patients with GAD in Japan fail to receive any treatment, and among those who do receive treatment, up to 32.5% do not perceive their treatment to be helpful. 3 It is worth noting that, in Japan, a slightly lower proportion of patients with GAD perceive their treatment to be beneficial than the patients with GAD in other high-income countries. 3 According to study estimates, each GAD patient would require 10 professionals for a 90% probability of GAD treatment to be perceived as helpful, while only 30% of patients would persistently try to seek help in the face of repeated unhelpful treatment encounters. 3 Currently, no guidelines are published by Japanese authorities for GAD diagnosis and treatment. It is also noteworthy that there are currently no specific medication -Abstract Truncated-
psychiatry,clinical neurology